Jonathan Tegge
2024
In 2024, Jonathan Tegge earned a total compensation of $10.5K as Former Interim Chief Financial Officer at InMed Pharmaceuticals, a 400% increase compared to previous year.
Compensation breakdown
| Option Awards | $10,500 |
|---|---|
| Total | $10,500 |
Tegge received $10.5K in option awards, accounting for 100% of the total pay in 2024.
Rankings
In 2024, Jonathan Tegge's compensation ranked 244th out of 244 executives tracked by ExecPay.
| Classification | Ranking | Percentile |
|---|---|---|
All | 244 out of 244 | 0th |
Division Manufacturing | 108 out of 108 | 0th |
Major group Chemicals And Allied Products | 44 out of 44 | 0th |
Industry group Drugs | 41 out of 41 | 0th |
Industry Pharmaceutical Preparations | 35 out of 35 | 0th |
Source: SEC filing on October 28, 2024.
Tegge's colleagues
We found five more compensation records of executives who worked with Jonathan Tegge at InMed Pharmaceuticals in 2024.
2024
Eric Adams
InMed Pharmaceuticals
Chief Executive Officer
2024
Michael Woudenberg
InMed Pharmaceuticals
Chief Operating Officer
2024
Eric Hsu
InMed Pharmaceuticals
Senior Vice President, Preclinical Research & Development
2024
Alexandra Mancini
InMed Pharmaceuticals
Senior Vice President, Clinical & Regulatory Affairs
2024
Netta Jagpal
InMed Pharmaceuticals